Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

4.21
+0.33008.51%
Post-market: 4.20-0.0101-0.24%19:47 EDT
Volume:1.84M
Turnover:7.59M
Market Cap:513.63M
PE:-5.37
High:4.22
Open:3.91
Low:3.91
Close:3.88
52wk High:7.55
52wk Low:2.12
Shares:122.00M
Float Shares:115.00M
Volume Ratio:0.93
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7836
EPS(LYR):-0.7836
ROE:148.50%
ROA:-33.92%
PB:-15.26
PE(LYR):-5.37

Loading ...

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire
·
Nov 24, 2025

Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Development Officer Matthew W. Davis

Reuters
·
Nov 12, 2025

Jim Cramer: Joby Is 'Losing Too Much Money'

Benzinga_recent_news
·
Nov 12, 2025

Lake Street Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

TIPRANKS
·
Nov 08, 2025

U.S. RESEARCH ROUNDUP-Blackline, Carmax, Expedia

Reuters
·
Nov 07, 2025

Aquestive Therapeutics Inc : Piper Sandler Raises Target Price to $8 From $5

THOMSON REUTERS
·
Nov 07, 2025

BRIEF-Aquestive Therapeutics, Inc. Q3 Income From Operations USD -11.479 Million

Reuters
·
Nov 06, 2025

Aquestive Therapeutics, Inc. Q3 Pretax Profit USD -15.446 Million

THOMSON REUTERS
·
Nov 06, 2025

BRIEF-Aquestive Therapeutics Announces Leadership Expansion To Support Growth

Reuters
·
Nov 04, 2025

Aquestive Therapeutics Expands Leadership Team Ahead of Anaphylm Launch

Reuters
·
Nov 04, 2025

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

THOMSON REUTERS
·
Nov 04, 2025

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler

GlobeNewswire
·
Nov 03, 2025

Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting

Reuters
·
Oct 30, 2025

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

GlobeNewswire
·
Oct 27, 2025

Aquestive Therapeutics Chief Medical Officer Carl N. Kraus Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Aquestive Therapeutics Inc. Officer Peter E. Boyd Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

THOMSON REUTERS
·
Oct 08, 2025

Aquestive Therapeutics Inc - New Patents Extend Anaphylm Protection Into 2037

THOMSON REUTERS
·
Oct 08, 2025

Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037

Reuters
·
Oct 08, 2025

Aquestive Therapeutics Inc. Officer Peter E. Boyd Reports Disposal of Common Shares

Reuters
·
Sep 30, 2025